Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage.
amelanotic melanoma
histology
melanoma
pigmentation
prognosis
risk factors
skin cancer
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
21
06
2023
received:
21
04
2023
accepted:
10
07
2023
medline:
2
11
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
The increasing number of melanoma patients makes it necessary to develop best possible strategies for prognosis assessment in order to recommend appropriate therapy and follow-up. The prognostic significance of tumor cell pigmentation has not been fully elucidated. Hematoxylin and eosin (H&E)-stained sections of 775 melanomas diagnosed between 2012 and 2015 were independently assessed for melanin pigment abundance by two investigators, and the impact on melanoma-specific survival was calculated. Unpigmented melanomas (n = 99) had a melanoma-specific survival of 67.7%, melanomas with moderate pigmentation (n = 384) had a melanoma-specific survival of 85.9%, and strongly pigmented melanomas (n = 292) had a melanoma-specific survival of 91.4% (p < .001). In an analysis of melanoma-specific survival adjusted for pT stage and pigmentation, we found a nonsignificant impact of pigmentation abundance with a hazard ratio of 1.277 (p = .74). The study presented here provides evidence in a German cohort that patients with pigmented melanomas have a more favorable prognosis than those diagnosed with nonpigmented melanomas. Moreover, the abundance of pigmentation already seems to provide a first prognostic estimate. However, it does not appear to provide significant additional value for prognostic assessment according to the AJCC 2017 pT classification.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
512-521Informations de copyright
© 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.
Références
Amaral, T. M. S., Hoffmann, M. C., Sinnberg, T., Niessner, H., Sülberg, H., Eigentler, T. K., & Garbe, C. (2020). Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. European Journal of Cancer, 125, 38-45. https://doi.org/10.1016/j.ejca.2019.10.027
Balch, C. M., Murad, T. M., Soong, S. J., Ingalls, A. L., Halpern, N. B., & Maddox, W. A. (1978). A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Annals of Surgery, 188(6), 732-742. https://doi.org/10.1097/00000658-197812000-00004
Barnes, B., Kraywinkel, K., Nowossadeck, E., Schönfeld, I., Starker, A., Wienecke, A., & Wolf, U. (2016). Bericht zum Krebsgeschehen in Deutschland 2016. Robert Koch-Institut.
Barnhill, R. L., Fine, J. A., Roush, G. C., & Berwick, M. (1996). Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 78(3), 427-432. https://doi.org/10.1002/(sici)1097-0142(19960801)78:3<427::Aid-cncr8>3.0.Co;2-g
Bellomo, D., Arias-Mejias, S. M., Ramana, C., Heim, J. B., Quattrocchi, E., Sominidi-Damodaran, S., Bridges, A. G., Lehman, J. S., Hieken, T. J., Jakub, J. W., Pittelkow, M. R., DiCaudo, D. J., Pockaj, B. A., Sluzevich, J. C., Cappel, M. A., Bagaria, S. P., Perniciaro, C., Tjien-Fooh, F. J., van Vliet, M. H., … Meves, A. (2020). Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precision Oncology, 4, 319-334. https://doi.org/10.1200/po.19.00206
Brinker, T. J., Kiehl, L., Schmitt, M., Jutzi, T. B., Krieghoff-Henning, E. I., Krahl, D., Kutzner, H., Gholam, P., Haferkamp, S., Klode, J., Schadendorf, D., Hekler, A., Fröhling, S., Kather, J. N., Haggenmüller, S., von Kalle, C., Heppt, M., Hilke, F., Ghoreschi, K., … Utikal, J. S. (2021). Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. European Journal of Cancer, 154, 227-234. https://doi.org/10.1016/j.ejca.2021.05.026
Brożyna, A. A., Jóźwicki, W., Roszkowski, K., Filipiak, J., & Slominski, A. T. (2016). Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget, 7(14), 17844-17853. https://doi.org/10.18632/oncotarget.7528
Buja, A., Bardin, A., Damiani, G., Zorzi, M., De Toni, C., Fusinato, R., Spina, R., Vecchiato, A., Del Fiore, P., Mocellin, S., Baldo, V., Rugge, M., & Rossi, C. R. (2021). Prognosis for cutaneous melanoma by clinical and pathological profile: A population-based study. Frontiers in Oncology, 11, 737399. https://doi.org/10.3389/fonc.2021.737399
Cabaço, L. C., Tomás, A., Pojo, M., & Barral, D. C. (2022). The dark side of melanin secretion in cutaneous melanoma aggressiveness. Frontiers in Oncology, 12, 887366. https://doi.org/10.3389/fonc.2022.887366
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes & Development, 20(24), 3426-3439. https://doi.org/10.1101/gad.406406
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., … McArthur, G. A. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine, 364(26), 2507-2516. https://doi.org/10.1056/NEJMoa1103782
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell, 6(6), 565-576. https://doi.org/10.1016/j.ccr.2004.10.014
Elder, D. E., Bastian, B. C., Cree, I. A., Massi, D., & Scolyer, R. A. (2020). The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Archives of Pathology & Laboratory Medicine, 144(4), 500-522. https://doi.org/10.5858/arpa.2019-0561-RA
Evans, J. L., Vidri, R. J., MacGillivray, D. C., & Fitzgerald, T. L. (2018). Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma. Surgery, 164(3), 589-593. https://doi.org/10.1016/j.surg.2018.04.016
Forchhammer, S., Abu-Ghazaleh, A., Metzler, G., Garbe, C., & Eigentler, T. (2022). Development of an image analysis-based prognosis score using Google's teachable machine in melanoma. Cancers (Basel), 14(9), 2243. https://doi.org/10.3390/cancers14092243
Gaggioli, C., Buscà, R., Abbe, P., Ortonne, J. P., & Ballotti, R. (2003). Microphthalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes. Pigment Cell Research, 16(4), 374-382. https://doi.org/10.1034/j.1600-0749.2003.00057.x
Gambichler, T., Tsagoudis, K., Kiecker, F., Reinhold, U., Stockfleth, E., Hamscho, R., Egberts, F., Hauschild, A., Amaral, T., & Garbe, C. (2021). Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. European Journal of Cancer, 143, 11-18. https://doi.org/10.1016/j.ejca.2020.10.016
Gerami, P., Cook, R. W., Wilkinson, J., Russell, M. C., Dhillon, N., Amaria, R. N., Gonzalez, R., Lyle, S., Johnson, C. E., Oelschlager, K. M., Jackson, G. L., Greisinger, A. J., Maetzold, D., Delman, K. A., Lawson, D. H., & Stone, J. F. (2015). Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clinical Cancer Research, 21(1), 175-183. https://doi.org/10.1158/1078-0432.Ccr-13-3316
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F., & for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. (2017). Melanoma staging: Evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67(6), 472-492. https://doi.org/10.3322/caac.21409
Goodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R. A., Larue, L., & Goding, C. R. (2008). Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Research, 68(19), 7788-7794. https://doi.org/10.1158/0008-5472.Can-08-1053
Grant, S. R., Andrew, T. W., Alvarez, E. V., Huss, W. J., & Paragh, G. (2022). Diagnostic and prognostic deep learning applications for histological assessment of cutaneous melanoma. Cancers (Basel), 14(24), 6231. https://doi.org/10.3390/cancers14246231
Hale, C. S., Qian, M., Ma, M. W., Scanlon, P., Berman, R. S., Shapiro, R. L., Pavlick, A. C., Shao, Y., Polsky, D., Osman, I., & Darvishian, F. (2013). Mitotic rate in melanoma: Prognostic value of immunostaining and computer-assisted image analysis. The American Journal of Surgical Pathology, 37(6), 882-889. https://doi.org/10.1097/PAS.0b013e31827e50fa
Hoek, K. S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., Schadendorf, D., & Dummer, R. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Research, 19(4), 290-302. https://doi.org/10.1111/j.1600-0749.2006.00322.x
Huvos, A. G., Shah, J. P., & Goldsmith, H. S. (1972). A clinicopathologic study of amelanotic melanoma. Surgery, Gynecology & Obstetrics, 135(6), 917-920.
Johannet, P., Coudray, N., Donnelly, D. M., Jour, G., Illa-Bochaca, I., Xia, Y., Johnson, D. B., Wheless, L., Patrinely, J. R., Nomikou, S., Rimm, D. L., Pavlick, A. C., Weber, J. S., Zhong, J., Tsirigos, A., & Osman, I. (2021). Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clinical Cancer Research, 27(1), 131-140. https://doi.org/10.1158/1078-0432.Ccr-20-2415
Kiprono, S. K., Chaula, B. M., & Beltraminelli, H. (2014). Histological review of skin cancers in African albinos: A 10-year retrospective review. BMC Cancer, 14, 157. https://doi.org/10.1186/1471-2407-14-157
Kulkarni, P. M., Robinson, E. J., Sarin Pradhan, J., Gartrell-Corrado, R. D., Rohr, B. R., Trager, M. H., Geskin, L. J., Kluger, H. M., Wong, P. F., Acs, B., Rizk, E. M., Yang, C., Mondal, M., Moore, M. R., Osman, I., Phelps, R., Horst, B. A., Chen, Z. S., Ferringer, T., … Saenger, Y. M. (2020). Deep learning based on Standard H&E Images of primary melanoma tumors identifies patients at risk for visceral recurrence and death. Clinical Cancer Research, 26(5), 1126-1134. https://doi.org/10.1158/1078-0432.Ccr-19-1495
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P. F., Hill, A., Wagstaff, J., Carlino, M. S., Haanen, J. B., Maio, M., Marquez-Rodas, I., McArthur, G. A., Ascierto, P. A., … Wolchok, J. D. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine, 373(1), 23-34. https://doi.org/10.1056/NEJMoa1504030
Larsen, T. E., & Grude, T. H. (1978). A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 2. The relation of cell type, pigmentation, atypia and mitotic count to histological type and prognosis. Acta Pathologica et Microbiologica Scandinavica, 86a(6), 513-522. https://doi.org/10.1111/j.1699-0463.1978.tb02078.x
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., Kuntzer, T., Michielin, O., Peters, S., Coukos, G., Spertini, F., Thompson, J. A., & Obeid, M. (2019). Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nature Reviews. Clinical Oncology, 16(9), 563-580. https://doi.org/10.1038/s41571-019-0218-0
Moreau, J. F., Weissfeld, J. L., & Ferris, L. K. (2013). Characteristics and survival of patients with invasive amelanotic melanoma in the USA. Melanoma Research, 23(5), 408-413. https://doi.org/10.1097/CMR.0b013e32836410fe
Okafor, O. C., & Onyishi, N. T. (2021). Primary cutaneous malignancies in nonalbino and albino Africans. International Journal of Dermatology, 60(2), 222-228. https://doi.org/10.1111/ijd.15312
Quaglino, P., Ribero, S., Osella-Abate, S., Macrì, L., Grassi, M., Caliendo, V., Asioli, S., Sapino, A., Macripò, G., Savoia, P., & Bernengo, M. G. (2011). Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single Centre observational cohort study. Surgical Oncology, 20(4), 259-264. https://doi.org/10.1016/j.suronc.2010.11.001
Que, S. K. T., Zwald, F. O., & Schmults, C. D. (2018). Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. Journal of the American Academy of Dermatology, 78(2), 237-247. https://doi.org/10.1016/j.jaad.2017.08.059
Ribero, S., Moscarella, E., Ferrara, G., Piana, S., Argenziano, G., & Longo, C. (2016). Regression in cutaneous melanoma: A comprehensive review from diagnosis to prognosis. Journal of the European Academy of Dermatology and Venereology, 30(12), 2030-2037. https://doi.org/10.1111/jdv.13815
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsova, I., Hauschild, A., Lorigan, P., Wolter, P., Long, G. V., Flaherty, K., Nathan, P., … Schadendorf, D. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England Journal of Medicine, 372(1), 30-39. https://doi.org/10.1056/NEJMoa1412690
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., … Ribas, A. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine, 372(26), 2521-2532. https://doi.org/10.1056/NEJMoa1503093
Sacchetto, L., Zanetti, R., Comber, H., Bouchardy, C., Brewster, D. H., Broganelli, P., Chirlaque, M. D., Coza, D., Galceran, J., Gavin, A., Hackl, M., Katalinic, A., Larønningen, S., Louwman, M. W. J., Morgan, E., Robsahm, T. E., Sanchez, M. J., Tryggvadóttir, L., Tumino, R., … Rosso, S. (2018). Trends in incidence of thick, thin and in situ melanoma in Europe. European Journal of Cancer, 92, 108-118. https://doi.org/10.1016/j.ejca.2017.12.024
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C., Petrella, T. M., Hamid, O., Zhou, H., Ebbinghaus, S., Ibrahim, N., & Robert, C. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 390(10105), 1853-1862. https://doi.org/10.1016/s0140-6736(17)31601-x
Slominski, A., & Goodman-Snitkoff, G. G. (1992). Dopa inhibits induced proliferative activity of murine and human lymphocytes. Anticancer Research, 12(3), 753-756.
Slominski, A., Paus, R., & Mihm, M. C. (1998). Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: Selective review and hypothesis. Anticancer Research, 18(5b), 3709-3715.
Slominski, A., Tobin, D. J., Shibahara, S., & Wortsman, J. (2004). Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological Reviews, 84(4), 1155-1228. https://doi.org/10.1152/physrev.00044.2003
Slominski, A., Zbytek, B., & Slominski, R. (2009). Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. International Journal of Cancer, 124(6), 1470-1477. https://doi.org/10.1002/ijc.24005
Thomas, N. E., Kricker, A., Waxweiler, W. T., Dillon, P. M., Busman, K. J., From, L., … Berwick, M. (2014). Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: A population-based study. JAMA Dermatology, 150(12), 1306-1314. https://doi.org/10.1001/jamadermatol.2014.1348
Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., & Bastian, B. C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Medicine, 5(6), e120. https://doi.org/10.1371/journal.pmed.0050120
Wellbrock, C., & Marais, R. (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. The Journal of Cell Biology, 170(5), 703-708. https://doi.org/10.1083/jcb.200505059